Early metastatic dissemination and evolution of disseminated cancer cells (DCCs) outside the primary tumor is one reason for the failure of adjuvant therapies because it generates molecular genotypes and phenotypes different from primary tumors, which still underlie therapy decisions. Since ERBB2 amplification in esophageal DCCs but not in primary tumor cells predict outcome, we aimed to establish an assay with diagnostic reliability for single DCCs or circulating tumor cells. For this, we evaluated copy number alterations of more than 600 single DCCs from multiple cancer types to define reference regions suitable for quantification of target regions, such as ERBB2. We then compared ERBB2 quantitative PCR (qPCR) measurements with fluorescent in situ hybridization (FISH) data of various breast cancer cell lines and identified the aberration-calling threshold. The method was applied to two independent cohorts of esophageal cancer patients from Hamburg (n 5 59) and D€ usseldorf (n 5 53). We found a high correlation between the single cell qPCR assay and the standard FISH assay (R 5 0.98) and significant associations between amplification and survival for both patient cohorts (Hamburg (HH), p 5 0.033; D€ usseldorf (D), p 5 0.052; pooled HH 1 D, p 5 0.002) when applied to DCCs of esophageal cancer patients. Detection of a single ERBB2-amplified DCC was the most important risk factor for death from esophageal cancer (relative risk 5 4.22; 95% CI 5 1.91-9.32; p < 0.001). In our study, we detected ERBB2-amplified cells in 7% of patients. These patients could benefit from anti-ERBB2 targeting therapies.
Esophageal cancer is worldwide one of the leading causes of cancer-related death and accounts for around 15,000 deaths per year in the United States alone. [1] [2] [3] [4] Both histological subtypes, squamous cell carcinoma and adenocarcinoma, are highly aggressive cancers and have currently limited treatment options. [3] [4] [5] Importantly, incidence rates of esophageal adenocarcinomas have increased over the past decades. 4 Due to advanced disease at diagnosis, <50% of esophageal cancer patients are eligible for surgical resection with curative intention. Furthermore, despite aggressive multimodal therapies, five-year-survival rates remain low (<40%) and drop dramatically to below 5% in the presence of metastasis. 3, 4 In search of new therapeutic options, targeted therapies are currently explored, using drugs directed against EGFR (ERBB1), ERBB2 6, 7 and MET. 8 ERBB2 appears as particularly attractive therapy target because (i) genomic profiling of the potential metastatic precursor cells, that is, disseminated cancer cells (DCCs) isolated from the bone marrow or lymph nodes, revealed activated ERBB2 as driver of metastatic progression in esophageal adenocarcinoma 9 ; (ii) amplification of the ERBB2 gene locus, present in 15-17% of primary esophageal cancers, is equally frequent in manifest metastases 10 ; (iii) selection of ERBB2-amplified clones in initially nonamplified esophageal cancer during the course of disease has been observed. 11 Furthermore, anti-ERBB2 treatment reduced metastasis in a spontaneously metastasizing xenograft model of ERBB2-positive esophageal adenocarcinoma. 12 However, despite these encouraging results, benefits for patient survival have been only modest so far, 13, 14 which may be due to inadequate patient stratification relying on the analysis of heterogeneous primary tumors. 15 Doubts about the stratification power of primary tumors are fueled by the observation that while single ERRB2-amplified DCCs predict poor outcome, 9 the amplification status of primary tumor cells had no impact on patient survival. [8] [9] [10] [15] [16] [17] This suggests that inclusion of the genetic status of DCCs may improve patient stratification in therapy trials.
Notably, DCCs in bone marrow and lymph nodes are rare (ranging from 1 to 10 per 10 6 screened cells) and mostly detected as either single cells or clusters of only 2-5 cells. 9 Therefore, assays are needed to reliably retrieve the ERBB2 status of single cells. Currently available methods of single cell analysis, such as the ERBB2 staining for circulating tumor cells (CTCs), as provided, for example, by the CTC-kit of CellSearchV R or the ERBB2 mRNA analysis of the AdnaTest, revealed inconsistent results. 18 Possibly, this is because mRNA and protein expression are subjected to transcriptional and (post-)translational regulation respectively and therefore are less stable than DNA changes. More importantly, protein and mRNA measurements may not reflect oncogene addiction resulting from genetic target activation. 19 The gold standard to measure ERBB2 gene amplifications, the fluorescent in situ hybridization (FISH) assay, while historically the first genetic assay applied to characterize DCCs, 20 failed to become widely used, most likely because of difficulties to guarantee hybridization for a single event and its limitation to few regions per cell. Since combinations of alterations are likely to become increasingly important, we developed a quantitative method of targeted copy number assessment for systemically spread cancer cells downstream of a comprehensive whole genome amplification method (WGA) now available as Ampli1
TM .
This WGA method is highly deterministic in that it uses the MseI restriction enzyme to cut single cell genomes, ligates adaptors to the sticky ends and employs a single PCR primer for amplification. Thereby, cell-to-cell variations introduced by random-priming (e.g., in multiple strand displacement methods) are excluded and variability is thus limited to minor differences of individual donor polymorphisms. The WGA method proved its reliability in hundreds of single cell experiments from clinical samples. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Furthermore, using deterministic WGA allows investigating several amplified oncogenes from the same single cell in parallel and enables subsequent development of targeted multiplexing assays. Last but not least, we established our quantitative PCR read-out assay such that it only requires widely available equipment fostering cost effective analysis of hundreds of clinical samples. Here, we describe an assay to quantify ERBB2 gene amplification in single DCCs or CTCs and its validation in patients with surgically treated esophageal cancer.
Materials and Methods

Patients
We analyzed DCC WGA products of patients from two independent, previously published studies, 9, 39 in which we investigated surgically treated esophageal cancer patients for bone marrow and lymph node DCCs at the University Hospital of Hamburg and the University Hospital D€ usseldorf (the subgroup of patients from 07/2005 to 2/2009 were included for the current investigation). Sample collection and analysis were approved by the Medical Ethics Committees of the University Hospital Hamburg-Eppendorf and of the Medical Faculty of the University of D€ usseldorf, respectively, and written informed consent was obtained from each patient before surgery. The clinical characteristics of the patients included into the current investigation (n 5 112) are detailed in Supporting Information Table S3 .
DCC isolation and WGA
Processing of bone marrow and lymph node samples to generate single cell suspensions for DCC detection on adhesive slides were performed as described by Stoecklein et al. 9 for the Hamburg collective and by Driemel et al. 39 for the D€ usseldorf collective. Briefly, 10 6 mononuclear cells plated on adhesive slides were screened for DCCs and single markerpositive cells were subsequently isolated via micromanipulation followed by WGA as previously published. 9 However, the DCC detection differed between the two independent cohorts: while the Hamburg samples were screened for DCCs with a chromogenic APAAP assay using the A45/BB3 antibody for anti-CK staining in bone marrow and the Ber-EP4 antibody for anti-EpCAM staining in lymph nodes, 9 
Generation of comparative genomic hybridization (CGH) histogram
Metaphase CGH profiles from single bone marrow or lymph node derived DCCs were loaded into the progenetix tool 40 (www.progenetix.net). Data were taken from references. [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fluorescence in situ hybridization of cell line arrays
Cell lines for FISH analysis were cultured and processed at the Department of Gynecology (Caritas-Hospital St. Josef, University of Regensburg, Germany). All cell lines underwent routine Mycoplasma testing using the PCR-based VenorV R GeM detection kit and were repeatedly found Mycoplasma-free. Cell line based experimental procedures were performed within a period of ten culture passages max. For FISH analysis, donor blocks of cell lines were generated by embedding cell pellets containing 3 million cells into paraffin blocks. From these donor blocks, core cylinders with a diameter of 1.5 mm each were manually punched with a thin-walled stainless steel tube and deposited into a recipient paraffin block. CLA sections were mounted on charged slides (SuperFrost TM Plus, Menzel GmbH, Braunschweig, Germany). FISH was performed using 1 N citric acid as heat pretreatment solution for 40 min at 958C. After washing slides in water they were air-dried. A ready to use pepsin solution (ZytoVision GmbH) was applied for 5 min at 378C. Slides were treated with 2 3 SSC for 5 min, dehydrated in an ethanol series, air dried and 5 lL of ERBB2/CEN17 dual color probe (ZytoVision GmbH, Bremerhaven, Germany) was applied as described in detail elsewhere. 41 Codenaturation of probe DNA and secondary mRNA structures was performed at 738C for 5 min. After hybridization over night at 378C, slides were washed at 508C in 4 3 SSC, 2 3 SSC, 1 3 SSC, supplemented with 0.3% Igepal (ICN Biomedicals), 5 min each. Finally, the slides were rinsed once with aqua dest. (1 min), air dried and counterstained with DAPI/Antifade solution (ZytoVision GmbH) and analyzed by epifluorescence microscopy using the AxioImager-Z1 (Zeiss, G€ ottingen, Germany). The gene/centromere ratio was calculated as mean out of 50 counted nuclei.
Quantitative PCR
Quantitative PCR was performed using a LightCycler instrument (Roche, Mannheim, Germany) and Fast Start Master SYBR Green Kits (Roche) using 1 mL of primary PCR products from the WGA diluted 1:100 in H 2 O. Relative quantification analysis was done using the LightCycler 480 software release 1.5.0 (Roche). The final protocol contained three primers within the ERBB2 locus and six reference genes on five different chromosomes (AGTR1: chromosome 3, OPN1SW: chromosome 7, CACNA1D: chromosome 3, GZMB: chromosome 14, RUFY2: chromosome 10 and SMYD1: chromosome 2). Primer sequences are displayed in Supporting Information Table S6 . A previously established external standard curve was used to calculate the PCR efficiency. Measurements showing unspecific products in the melting curve analysis were discarded from further statistical analysis. All samples were run in duplicates.
Data processing and statistical evaluation
The LightCycler data consisted of calibrated target-reference qPCR ratios ratio tar with DCP x 5CP x;p x ð Þ 2CP cal;p x ð Þ . 42 Here, E x denotes the PCR efficiency of primer x, CP x;p x ð Þ the CP-value of x measured on plate p(x), and CP cal;p x ð Þ the calibrator CP-value measured on plate p(x). qPCR ratios were subsequently transformed to the log 2 -scale. Reference-reference log 2 -ratios in Figure 1b single calibrated log 2 -qPCR values for calculating the moderated t-statistic as described in Refs. 43 and 44. The median polish-based evaluation method provides summary statistics by a three-step process. First, we calculated target-reference pair-specific effects according to the original additive median polish model 45 using the 18 (53 3 6) target-reference log 2 -ratios (per sample) of normal control cells. Second, these effects were removed from the tumor cell data, and third the median of the adjusted log 2 -ratios were calculated.
Because application of some conventional outlier methods, like Hampel's identifier and generalized extreme studentized deviate, to our data were not fully satisfactory, we developed a novel outlier-correction method. Briefly, up to a ratio O/ S 5 1/3 of outliers were allowed for the target and reference primer sets, with O denoting the number of outliers and S the primer set size. Specifically, O/S 5 1/3 for targets and O/ S 5 (1 or 2)/6 for references. For each allowed O and S value, distance-based outlier statistics were calculated by drawing 10 5 random resamples from the original data. Outlier statistics were then used to detect outliers according to confidence level. The actual confidence level employed was chosen according to the fraction of outliers present in the original data. This was estimated to be 0.20 by comparing to Figure  1c and visual assessment of the final results [in Fig. 1c , the observed fractions of 0.30-0.32 for reference-reference pair outliers correspond to fractions of 0.16-0.19 (binomial distribution) or 1/9-2/9 (hypergeometric distribution] of single reference outliers). Similar to Winsorizing, detected outliers were reset to the outlier-defining distance threshold. The performance of our method is demonstrated in Supporting Information Figure S3 . To exclude spuriously low p-values for isolated amplification threshold values (e.g., threshold 0.937 in Fig. 4b ), p-values in Table 1 are maxima across sliding windows (support) of length 0.025 obtained using thresholds between 0.9 and 0.999.
Statistical analyses were performed using the R programming language. 46 Cox-regression analysis was also performed using SPSS statistics 24 (IBM).
Results
Selection of suitable reference primers
To quantify selected gene number alterations by qPCR, we first defined reference regions to be compared with the ERBB2 target region. Centromeric chromosome regions as (Fig. 1a) . Our selection criteria for reference regions and genes were (i) sites rarely aberrant across all DCCs from the various tumors; (ii) sites rarely included in copy number alterations of individual cancer types; (iii) sites not known to harbor genes with a role in cancer progression. According to these criteria, we designed nine reference primer pairs for the genes AGTR1, OPN1SW, CACNA1D, CASQ2, GZMB, RUFY2, SMYD1, TFAM and TMPO located on MseI fragments of size up to 500 bp because we had previously found 34 that amplification efficiency is optimal for DNA amplicons of this length. We analyzed 224 diploid control cells for three target primers (designated here ERBB2-310, ERBB2-315 and ERBB2-E) and the above nine reference primers. These cells were either cells from healthy donors (n 5 64 cells) or patient-matched controls from cancer patients that did not stain for our DCC markers (CK8/18/19 in bone marrow or EpCAM in lymph nodes, n 5 160 cells). For assessing the suitability of reference primers, we transformed normalized expression ratios of reference-reference pairs obtained using the LightCycler software to the log 2 -scale and plotted these log-ratios for each reference primer across all paired references and all cells (Fig.  1b) . Ideally, the result would be a narrow zero-centered distribution of log-ratios. However, we observed a number of outliers and assessed reference primer quality by counting outliers as defined by the limits 21 and 1 (Fig. 1c) . Subsequently, primers TFAM, TMPO and CASQ2 were discarded according to their high outlier frequency. This defined the six low variability primers AGTR1, OPN1SW, CACNA1D, GZMB, RUFY2 and SMYD1 as references for the subsequently applied assay.
Sample and assay quality control (QC)
We recently found that QC of single cell WGA products is a key for diagnostic use. 47 Therefore, we systematically assessed measurement quality. For clinical samples, we defined two quality measures, one for sample WGA products (QC level S1-3, with S1 representing best quality) and one for subsequent qPCR measurement of these WGA products (QC level P1-3, with P1 representing best quality). Lower quality levels are inclusive of higher quality levels, e.g. QC level 2 comprises both QC level 1 and 2. The exact definition of applied QC levels is detailed in Supporting Information Table S1 .
Comparison of FISH and single cell qPCR
The underlying rationale of our approach consists of ERBB2 amplification detection by quantifying differences between target and reference qPCR values. To this end, we explored two statistical methods, moderated t-statistics and a median polish-based evaluation method (Methods). Both statistics were first applied to the normal cell cohort with results fitted by normal distributions. Subsequently, these probability distributions served to classify cells as either ERBB2-amplified or not amplified.
We first tested our approach on seven breast cancer cell lines (BT549, MDA-MB468, ZR75.1, MDA-MB453, MDA-MB361, SKBR3 and BT474) with known ERBB2 copy number alterations, 41 for which we also performed FISH analysis.
The ERBB2 FISH ratio was assessed as the number of gene copies relative to the number of centromeres based on evaluation of 50 nuclei per cell line. Ratios were 0.81 (BT549), (Fig. 2c) . Furthermore, results for BT549 and ZR75.1 indicated that higher thresholds might be required for median polish as compared to moderated t-statistics (Fig. 2c) .
Detection of ERBB2 amplification in clinical samples of esophageal cancer patients
For comparison with patient-derived DCCs isolated from adhesion slides, we used only those 120/224 control cells that had been identically treated during the staining and isolation procedure. The number of cells that entered our final study depended on QC level and ranged between 86 (S1/P1) and 120 (S3/P3) for normal control and between 60 (S1/P1) and 142 (S3/P3) for candidate tumor cells (Supporting Information Table S2 ). The intermediate QC level S2/P2 was selected for graphical display and corresponds to 103 normal control and 122 candidate tumor cells isolated from esophageal cancer patients treated in Hamburg (HH) or D€ usseldorf (D). We applied median polish and moderated t-statistics and used normal distributions to calculate amplification probabilities for both methods (Figs. 3a-3e ). Since moderated t-statistics can be sensitive to outliers due to its dependence on mean values and standard deviation, we tested the application of an outlier correction (Methods). This increased the correlation between the amplification probabilities of both methods from 0.80 to 0.91 (Fig. 3f) . Example data of amplified and nonamplified cells as well as outlier correction are shown in Supporting Information Figures S1-S3.
Survival analysis
We evaluated our detection assay for single DCCs isolated from patients with esophageal cancer. The first cohort comprised patients from Hamburg previously analyzed in Ref. 9, the second cohort was recruited in D€ usseldorf. Patient baseline characteristics are provided in Supporting Information Table S3 and were found to be very similar, except for the proportion of adeno-and squamous cell carcinomas and applied therapy (marginally significant p-values). Of the 142 DCCs isolated from cancer patients, 95 were isolated from 38 patients fulfilling stringent selection criteria for survival analysis useful in clinical DCC research. These criteria were (i) minimum survival time of 3 months, (ii) primary tumor resection status R0 or R1 (treatment with curative intention) and (iii) absence of distant metastases. Depending on applied QC criterion and admissible resection status the number of patients with at least one detected cell ranged between 18 (S1/P1, R0), 33 (S2/P2, R0 1 R1) and 38 (S3/P3, R0 1 R1). For survival analysis we also included 69 (R0) or 79 (R0 1 R1) patients with no DCCs detected (see Supporting Information Table S4 for a complete listing). However, DCCpositive patients for whom we could not obtain high-quality qPCR data (e.g., cell loss during isolation or poor quality of the WGA product) were considered as non-informative and excluded from the survival analysis. Patients were classified as DCC-ERBB2-amplified when at least one DCC showed ERBB2 amplification. DCC amplification calling depended on the threshold chosen. The FISH experiments indicated thresholds of 0.95 for t test statistics and 0.975 for median polish (Fig. 2c) , values that proved to be appropriate also for patient-derived tumor cells (Fig. 3) . Evaluating thresholds between 0.9 and 0.999 that best discriminate between patient groups with long and short survival according to logrank test p-values, we noted that both methods enable excellent discrimination using the thresholds identified above. Consistently, we observed that threshold intervals were slightly upshifted for median polish as compared to t-statistics (Figs. 4a  and 4b ).
Systematic assessment of QC levels and resection status demonstrated that the impact of ERBB2 amplification of DCCs on survival was very robust (Table 1) . Comparing patients with ERBB2-amplified DCCs (DCC1/ERBB21) against all other patients (i.e., DCC1/ERBB2-and DCC-patients), revealed ERBB2 amplification as a significant risk factor, regardless of resection status, statistical method or quality level (Table 1) . Limiting the comparison to DCC1 patients (i.e. comparing DCC1/ERBB21 vs. DCC1/ERBB2-) we noted an impact of QC level (Table 1 ). Sample quality (S1-3) had a systematic influence on p-values in that the intermediate level S2 resulted in the lowest p-values, probably best compromising between effects of case number and sample quality. The influence of qPCR quality (P1-3) was less systematic (Table 1) , while consistency between results required exclusion of low quality levels (S2/P3, S3/P2, S3/P3; Supporting Information Figure S4) . Consequently, QC criteria S2/P2 applied to patients treated with curative intent (R0 1 R1) were used to define and evaluate the combined patient cohort. For amplification calling, we applied the slightly more robust median polish method. Kaplan-Meier survival curves of the two cohorts from Hamburg (n 5 59) and D€ usseldorf (n 5 53) are shown separately (Figs. 4c and 4d ) and together as a pooled analysis (n 5 112; Fig. 4e ) demonstrating higher statistical significance for the combined study. Notably, ERBB2 amplification in single DCCs was about three times as frequent in adenocarcinoma (30.4%, 17/56) as compared to squamous cell carcinoma (10.3%, 3/29), as has similarly been reported in the literature. 9, 10 Amplification in single cells from bone marrow (23.9%, 11/46) and lymph nodes (23.1%, 9/39) was equivalent (Supporting Information Table S5 ). ERBB2 amplification of DCCs was assessed a significant risk factor in both univariable and multivariable Cox-regression analysis [relative risk 5 3.13 (p 5 0.003) and 4.22 (p < 0.001), respectively; Table 2 ].
Discussion
Here, we present a reliable diagnostic assay for the detection of ERBB2 amplifications in single DCCs and demonstrate that ERBB2 amplification in DCCs is significantly associated with short survival in esophageal cancer patients. Since others and we have previously shown that ERBB2 amplification in the primary tumor -unlike detection of this molecular change in single DCCs -does not predict poor outcome, 9, 10, 17 this finding may indicate that ERBB2-amplified DCCs will also predict therapy response. Therefore, we propose testing the predictive value of the assay described here for application with anti-ERBB2 strategies in a prospective clinical study in operable esophageal cancer patients. This is corroborated by clinical data in metastasized esophageal cancer 14 as well as by strong preclinical data demonstrating a better response to anti-ERBB2 treatment of a DCC-derived esophageal cancer cell line compared to a cell line derived from the matched primary tumor 9 and by different xenograft mouse models in which anti-ERBB2 treatment successfully suppressed metastatic development. Clearly, single cell characterization in a clinicaldiagnostic setting requires a reliable assay. We addressed this issue by covering three aspects. First, we compared our single cell assay against the current gold standard of gene amplification measurement, the FISH method, and found excellent correlation (R 5 0.98) between both assays. Notably, the FISH ratio was obtained by averaging 50 nuclei per cell line, whereas single cell PCR provided values for individual cells. Therefore, heterogeneity is not reflected in FISH values while it was clearly present in all cell lines. Despite this limitation, single cell measurements accurately reflected ERBB2 status.
Second, we defined sample and assay quality measures. We stratified our data according to sample quality (single cell WGA) and qPCR quality and found that sample quality (S1-3) had a systematic influence on logrank test-based p-values in survival analysis. The influence of qPCR quality (P1-3) was less systematic. Lowest qPCR quality (P3), however, resulted in a significant discrepancy between results with and without outlier correction for moderated t-statistics (S2-3), and for the lowest combined quality (S3/P3) a strong unexpected down shift of applicable amplification thresholds for the median polish-based statistic occurred. This indicates that only samples with medium or high quality should be used for diagnostic purposes. For these samples, outliers had a minor effect and both statistical methods gave highly similar results. Excluding lowest PCR-quality (P3), minimum p-values occurred for intermediate combined quality (S2/P2), probably as a tradeoff between case number and sample quality.
Third, we selected the very important reference loci from our DCC database, including DCCs not only from esophageal cancers but from many other cancer types as well. Thus, the selected reference sites can also be used for other cancer types, such as breast cancer, 47, 49 for which the disparity Tables S4). 2 Dichotomous clinical data are listed as dichotomized data. Lymph node status is treated as dichotomous since for some cases only dichotomous data were provided. Non-dichotomized data underlying ERBB2 and DCC are identical (no DCC 5 0, non-amplified DCC 5 1, amplified DCC 5 2). Dichotomous splitting is defined in parentheses. Right hand side conditions (e.g., male) carry the higher risk if relative risk >1. Notably, relative risk values are comparable only between risk factors of the same range (e.g., the 0/1-coded dichotomized data used here).
between primary tumors and emerging systemic disease regarding ERBB2 status is well known. 18, 32 Application of this assay to two independent patient cohorts that were treated at two different hospitals confirmed the prognostic impact of ERBB2 amplification in single DCCs, both in uni-and multivariable analysis. In fact, ERBB2 amplification in DCCs was the most important risk factor for the combined cohort. In our study, 7% of esophageal cancer patients harbored ERBB2-amplified DCCs, a number that is likely to increase as detection methods for DCCs are improved. For this, a variety of assays are being developed that, similar to CTC enrichment, 50 exploit microfluidics, cell filtration and antibody-based sorting approaches. None of these advanced technologies were applied in the current study to enrich and isolate DCCs from lymph node and bone marrow. In future studies, such highly sensitive methods for DCC detection and the subsequent molecular profiling may be compared with results from CTCs that might have complementary value, especially for longitudinal monitoring. CTCs seem to be particularly rare in early stage esophageal cancer 51 and increasing the analyzed blood volume using, for example, diagnostic leukapheresis 52 may be necessary. Once, cell detection and isolation issues have been resolved, the method described here will allow reliable, fast and inexpensive assessment of ERBB2 or other therapeutically relevant gene amplifications in a significant number of cancer patients and may be implemented for patient stratification in prospective clinical trials.
